The name “ROW Foundation” traces back to when OWP’s and ROW’s co-founder, Scott Boyer, was working as a consultant in the pharmaceutical industry. “One day I was analyzing market research data about a new drug,” Scott recalls. “The wealthy and emerging markets were grouped together on the charts and graphs. Then there was this small, lonely bar on the far end of the chart titled ‘ROW.’ It stood for ‘Rest of World.’” Internalizing the data, Scott imagined how unfortunate it would be if he were someone with a significant disease like epilepsy in one of these ROW countries.
In 2014, Scott and his business partner, Bruce Duncan, launched the ROW Foundation in tandem with a startup company, One World Pharmaceuticals (OWP). OWP is a for-profit business that markets effective and inexpensive epilepsy and psychiatry medications. OWP was designed from the ground up to serve as a long-term financial engine for the nonprofit foundation.
Beyond receiving revenues, ROW is also a shareholder in OWP, meaning that it is guaranteed a constant and reliable income stream from OWP’s success. Beyond that, OWP provides an ongoing and sustainable source of medication to ROW for its work around the world. Scott likes to call this approach “Social Enterprise 2.0”.
Through our partnership with OWP, ROW has granted millions of dollars in life-saving treatment medication, diagnostic equipment, and epilepsy- and psychiatry-specific training opportunities. Just last month, ROW reached another important milestone—$10 million in cumulative grants made to partner organizations in 25 countries. Our social enterprise model is working!
For more information about the unique OWP/ROW partnership, request the free booklet, One World, One Standard. Stay tuned in the months ahead for news about the launch of an exciting new partnership to expand epilepsy care in rural India!
If you would like to help ROW establish and extend our partnerships with epilepsy-related organizations you can get in touch with us by email at: email@example.com.